Prognostic Factors in Hepatocellular Carcinoma Management

Prognosis in hepatocellular carcinoma (HCC) is determined by a constellation of tumour biology, host liver function and treatment modality. Tumour‐related parameters such as size, number of nodules and macroscopic or microvascular invasion remain central predictors of recurrence and survival. Serum biomarkers including α-fetoprotein (AFP), PIVKA-II and markers of systemic inflammation provide non-invasive stratification of risk. Liver functional reserve, assessed by scores such as Child-Pugh or albumin–bilirubin (ALBI) grade, modulates therapeutic choice and survival estimates. Recent efforts have focused on integrating these variables into multivariable models—nomograms, risk calculators and machine-learning classifiers—to personalise surveillance intervals and adjuvant strategies. The advent of data-mining and decision-tree approaches has further refined prognostic algorithms for specific aetiologies, such as nonalcoholic fatty liver disease (NAFLD) or viral hepatitis, underscoring the heterogeneity of HCC patients. Clinically, these prognostic frameworks guide selection between resection, ablation, transplantation or systemic therapy, and inform the design of trials for adjuvant or neoadjuvant agents. Globally, standardising prognostic assessment enhances comparability of outcomes and equitable allocation of resources.

Research from Nature Portfolio

A comprehensive data-mining study of patients with NAFLD-related HCC employed random forest analysis and decision-tree algorithms to derive a two-tier prognostic profile. The foremost determinants of survival were receipt of curative intervention (hepatectomy or radiofrequency ablation) and pre-treatment serum albumin level. Patients treated with curative intent and albumin ≥3.7 g/dL constituted a favourable group with markedly higher five-year survival. This algorithm offers a transparent approach to risk stratification, facilitating individualised clinical management in a rapidly growing subgroup of HCC patients.

Prognostic Factors in Hepatocellular Carcinoma Management publication trend

The graph below shows the total number of articles in prognostic factors in hepatocellular carcinoma management across all publications each year (not limited to Nature Index journals).

Technical terms

Nomogram: A graphical tool that integrates multiple prognostic variables to estimate individual risk of an outcome.

Albumin–bilirubin (ALBI) grade: A model for liver function assessment based on serum albumin and bilirubin levels.

Microvascular invasion: Presence of tumour cells within small blood vessels on histology, indicating aggressive biology.

Monocyte-to-lymphocyte ratio (MLR): An inflammatory index calculated from peripheral blood counts, linked to tumour-promoting inflammation.

PIVKA-II: Protein induced by vitamin K absence or antagonist-II, a tumour‐associated biomarker used alongside AFP.

References

1. A prediction model based on machine learning: prognosis of HBV-induced HCC male patients with smoking and drinking habits after local ablation treatment. Frontiers in Immunology (2025).
2. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. Journal of Hepatology (2018).
3. A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. Scientific Reports (2018).
4. Inflammatory indexes in preoperative blood routine to predict early recurrence of hepatocellular carcinoma after curative hepatectomy. BMC Surgery (2021).